share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC ·  Aug 20 19:04

Summary by Futu AI

SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorder therapies, has announced the enrollment and dosing of the first five patients in its clinical trial for SCI-210, a treatment for autism spectrum disorder (ASD). The trial is being conducted at the Soroka Medical Center in Israel and involves a double-blind, randomized, and placebo-controlled study to compare the efficacy of SCI-210 against standard CBD monotherapy in managing ASD symptoms. SciSparc plans to enroll 60 subjects aged between five and 18 over a 20-week period. The company aims to commercialize SCI-210 in Israel first, followed by other countries, pending regulatory approvals. The trial's primary efficacy metrics include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement...Show More
SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorder therapies, has announced the enrollment and dosing of the first five patients in its clinical trial for SCI-210, a treatment for autism spectrum disorder (ASD). The trial is being conducted at the Soroka Medical Center in Israel and involves a double-blind, randomized, and placebo-controlled study to compare the efficacy of SCI-210 against standard CBD monotherapy in managing ASD symptoms. SciSparc plans to enroll 60 subjects aged between five and 18 over a 20-week period. The company aims to commercialize SCI-210 in Israel first, followed by other countries, pending regulatory approvals. The trial's primary efficacy metrics include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement, and the effective therapeutic dose. The trial design was advised by the National Autism Research Center in Israel. SciSparc's CEO, Oz Adler, expressed optimism about the trial's progress and its potential to contribute new scientific data for the treatment of ASD. SciSparc is also involved in drug development programs for other conditions, including Tourette Syndrome, Alzheimer's disease, pain, and status epilepticus, with a focus on cannabinoid pharmaceuticals.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.